ULTOMIRIS® (ravulizumab) Receives Marketing Authorization from European Commission for Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)

104

BOSTON–(BUSINESS WIRE)–ULTOMIRIS® (ravulizumab) Receives Marketing Authorization from European Commission for Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH) ….

 

 

 

 

 

http://www.businesswire.com/news/home/20190703005355/en/ULTOMIRIS%C2%AE-ravulizumab-Receives-Marketing-Authorization-European-Commission